Welcome to our dedicated page for Curevac B.V. SEC filings (Ticker: CVAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CureVac N.V. (CVAC) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures as a foreign private issuer. CureVac files reports with the U.S. Securities and Exchange Commission primarily on Form 20-F and Form 6-K, reflecting its status as a non-U.S. company listed on Nasdaq. These filings provide detailed information on CureVac’s mRNA-focused business, financial condition, risk factors, and material events.
Form 6-K submissions frequently include press releases on quarterly and interim financial results, business updates, and voting results from shareholder meetings. For example, CureVac has furnished 6-Ks that attach press releases on first, second, and third quarter 2025 results, interim condensed consolidated financial statements and management’s discussion and analysis as of June 30, 2025, and tabulations of votes from its annual and extraordinary general meetings. These documents discuss revenue contributions from partners such as GSK, BioNTech, and CRISPR Therapeutics, cash and cash equivalents, restructuring impacts, and licensing and settlement agreements.
Other 6-K filings cover corporate actions and the planned transaction with BioNTech SE, including the convening of an extraordinary general meeting, the public exchange offer for all outstanding CureVac shares, and shareholder approvals of proposals related to a legal downstream merger and post-offer reorganization. These filings are also referenced as being incorporated by reference into BioNTech’s registration statement on Form F-4 for the exchange offer.
On Stock Titan, users can access these SEC filings with real-time updates from EDGAR and AI-powered summaries that explain the key points of lengthy documents, such as interim financial statements, transaction-related disclosures, and meeting results. The platform also helps surface relevant items across CureVac’s filing history, allowing readers to quickly identify trends in revenue sources, litigation and intellectual property matters, cash runway commentary, and the progression of the BioNTech acquisition process.
BioNTech SE launched an exchange tender offer for all CureVac N.V. ordinary shares. Each CureVac share can be exchanged for BioNTech American Depositary Shares (ADSs) based on a formula equal to $5.4641 divided by the 10-day BioNTech ADS volume‑weighted average price (VWAP) ending five trading days before the expiration. The exchange ratio is capped at 0.04318 BioNTech ADSs per CureVac share if the VWAP is ≥ $126.55, and floored at 0.06476 if the VWAP is ≤ $84.37.
The offer is open until 9:00 a.m. New York City time on December 3, 2025, unless extended or terminated in accordance with the purchase agreement. This is a stock‑for‑stock offer registered on Form F‑4 for the BioNTech ADSs to be issued. CureVac had 225,181,647 shares outstanding as of October 17, 2025; this is a baseline figure, not the amount being exchanged.
BioNTech SE launched a public exchange offer to acquire all outstanding CureVac N.V. shares, registering and offering 15,061,575 new BioNTech ADSs in exchange. Each CureVac share will receive a number of ADSs equal to $5.4641 divided by the BioNTech ADS VWAP, subject to a collar: the exchange ratio is 0.04318 if VWAP ≥ $126.55 and 0.06476 if VWAP ≤ $84.37. Fractional ADSs will be settled in cash based on the VWAP.
The offer commenced on October 21, 2025 and initially runs until December 3, 2025, with the final exchange ratio set on November 25, 2025. A subsequent offering period of at least 10 business days will follow acceptance. Closing is conditioned on at least 80% of CureVac’s share capital tendered (reducible to 75% under certain circumstances), required regulatory approvals, and CureVac shareholder resolutions. BioNTech will not receive cash proceeds from the offer; estimated costs are about €17.5 million. Holders representing roughly 57% of CureVac shares signed tender and support agreements. The Offer ADSs will trade on Nasdaq under BNTX.
BioNTech SE launched an exchange offer to acquire all outstanding CureVac shares by issuing 15,061,575 newly registered ADSs of BioNTech in the UK offer described here. Holders of CureVac shares will receive BioNTech ADSs based on an exchange ratio equal to $5.4641 divided by the BioNTech ADS VWAP, with a collar fixing the ratio at 0.04318 if VWAP is ≥ $126.55 and at 0.06476 if VWAP is ≤ $84.37. Fractional ADSs will be paid in cash based on the VWAP.
The offer commences on October 21, 2025 and initially expires at 9:00 a.m. New York time on December 3, 2025, followed by a subsequent offering period of not less than 10 business days. Closing is subject to conditions including at least 80% of CureVac share capital tendered (reducible to 75% in certain circumstances), required regulatory approvals, no specified material adverse effects, and CureVac shareholder resolutions. BioNTech will not receive cash proceeds from the offer.
Support agreements covering approximately 57% of CureVac shares have been signed. As context, BioNTech notes an expected decrease in BioNTech shareholders’ aggregate percentage ownership of between 5.9% and 4.0%, depending on the final exchange ratio.
CureVac N.V. submitted a Form 6-K to provide investors with updated mid‑year information. The filing furnishes unaudited interim condensed consolidated financial statements as of June 30 and for the three and six months ended June 30, 2025 and 2024. It also includes a Management’s Discussion and Analysis of financial condition and results of operations for the six‑month periods ended June 30, 2025 and 2024, offering narrative context around the company’s performance and business updates.
GSK plc reports beneficial ownership of 16,591,937 Common Shares of CureVac N.V., representing 74% of the outstanding class based on 225,172,749 shares. These shares are held of record by Glaxo Group Limited (GGL), an indirect wholly-owned subsidiary. GSK acquired the shares through an initial contribution in connection with CureVac's IPO and a later follow-on purchase, with those prior purchases funded from GGL's internal resources.
The filing discloses that GGL entered a Tender and Support Agreement with BioNTech SE under which GGL agreed to tender all its Common Shares into BioNTech's exchange offer, vote for proposals to facilitate the offer, vote against Alternative Acquisition Proposals and, subject to conditions, terminate certain pre-IPO ISA rights in respect of GGL as of the offer's first settlement date.
Ownership update: Germany’s state bank KfW reports beneficial ownership of 112.84 m CureVac (CVAC) common shares—50.1 % of the 225.17 m shares outstanding—of which 29.87 m are held directly and 82.97 m are subject to an existing Shareholders’ Agreement with dievini/Hopp-affiliated entities.
New agreement: On 31 Jul 2025 KfW executed a Tender and Support Agreement with BioNTech SE (“Buyer”). Acting under a federal mandate and fully indemnified by the German government, KfW must (1) tender all of its shares into the Buyer’s forthcoming Exchange Offer detailed in the 12 Jun 2025 Purchase Agreement, (2) vote for transaction-related proposals and against alternatives, (3) observe interim restrictions on share actions, and (4) waive rights of first refusal and, at closing, terminate the Shareholders’, Relationship and related investment agreements.
Implications: The commitment by CureVac’s controlling 50 % shareholder materially increases the likelihood that the Exchange Offer will reach its minimum acceptance threshold and that the subsequent post-offer reorganisation can proceed. No deal price, exchange ratio or timeline changes are disclosed in this amendment.
CureVac filed a Form 6-K reporting the completion of its annual general meeting of shareholders held on June 26, 2025. The filing primarily serves to notify the submission of voting results from the meeting.
Key Points:
- The company submitted final tabulation of shareholder votes from its annual general meeting
- Document was signed by CEO Alexander Zehnder
- Filing includes Exhibit 99.1 containing the detailed voting results
- Company confirms it files annual reports under Form 20-F
The filing is purely administrative in nature, serving as a notice of foreign private issuer. The information provided in this Form 6-K is not deemed "filed" under Section 18 of the Securities Exchange Act and does not carry the associated liabilities or incorporation by reference under the Securities Act of 1933 or Exchange Act.
CureVac N.V. (CVAC) filed a Form 6-K to notify investors that it issued a press release on June 24, 2025 detailing the voting results from its Annual General Meeting of shareholders. No financial performance metrics, strategic transactions, or operational updates were included in the filing. The company also clarified that the information, including Exhibit 99.1 (the press release), is furnished—not filed—and therefore is not subject to Section 18 liabilities of the Exchange Act nor incorporated by reference into other SEC filings.